Florida condos are a popular real estate option for people living in the Sunshine State, especially if it has an ocean view. However, a condo crisis is impacting condo owners throughout Florida ...
Milestone Pharmaceuticals Inc. received FDA approval for CARDAMYST, a nasal spray for acute PSVT episodes, but faces a challenging commercialization path. The PSVT market is crowded with effective, ...
The PDUFA date for CARDAMYST™ is set for March 27, 2025, indicating a lengthy approval timeline that could delay commercialization and revenue generation for the company. The reliance on the FDA's ...
Running a company can be a demanding journey filled with constant challenges and responsibilities. Amid the hustle of daily operations, it’s easy to become so focused on what’s next that we overlook ...
$82.6 million in Cash at September 30; Successful Equity Offering and Amended Royalty Purchase Agreement Provide Resources for Successful Launch MONTREAL and CHARLOTTE, N.C., Nov. 12, 2025 (GLOBE ...
There was no revenue recorded for the fourth quarter or full year ended December 31, 2024, compared to $1.0 million in 2023, indicating potential challenges in generating income. The company reported ...
Generative AI has become a key part of coding workflows, but most companies struggle to track its use, let alone its return on investment. Israeli startup Milestone hopes to help with a platform ...
Founded during a time when Black, Latino, and Asian characters were rarely prioritized in mainstream superhero comic book publishing, Milestone Comics was established with the purpose of directly ...
PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback